Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system

被引:23
|
作者
Zimmerman, Robert S. [1 ]
Hobbs, Todd M. [2 ]
Wells, Brian J. [3 ]
Kong, Sheldon X. [2 ]
Kattan, Michael W. [4 ]
Bouchard, Jon [2 ]
Chagin, Kevin M. [4 ]
Yu, Changhong [4 ]
Sakurada, Brian [2 ]
Milinovich, Alex [4 ]
Weng, Wayne [2 ]
Bauman, Janine M. [4 ]
Pantalone, Kevin M. [1 ]
机构
[1] Cleveland Clin, Endocrinol, Cleveland, OH 44106 USA
[2] Novo Nordisk, Plainsboro, NJ USA
[3] Wake Forest Sch Med, Clin & Translat Sci Inst, Winston Salem, NC USA
[4] Cleveland Clin, Quantitat Hlth Sci, Cleveland, OH 44106 USA
来源
DIABETES OBESITY & METABOLISM | 2017年 / 19卷 / 11期
关键词
glucagon-like peptide-1 receptor agonist; cardiovascular risk; cardiovascular disease; mortality; type-2; diabetes; PROTAMINE HAGEDORN INSULIN; TO-TARGET TRIAL; GLYCEMIC CONTROL; BASAL INSULIN; COMBINATION THERAPY; PLUS METFORMIN; NPH INSULIN; GLARGINE; PREDICTORS; HYPOGLYCEMIA;
D O I
10.1111/dom.12969
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To assess the potential impact of glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure on cardiovascular disease (CVD) and mortality outcomes in patients with type 2 diabetes (T2D), using a large retrospective cohort. Research Design and Methods: Patients who had T2D between 2005 and 2014 (N = 105 862) were identified from the electronic health record system at Cleveland Clinic using a validated electronic phenotype. A time-dependent, Cox, multiple regression analysis was used to assess the association between GLP-1RA exposure and risk of acute myocardial infarction (AMI), stroke/cerebrovascular accident (CVA), and overall mortality, as well as the composite of all three outcomes. The findings were further evaluated by assessing the effect of GLP-1RAs on the same variables in patients with and without prior CVD. The model adjusted for differences in demographic information, hypertension, laboratory/vital signs, history of outcomes, and T2D medications. Results: There were significantly lower rates of AMI (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.65 to 0.99; P =.045), CVA (HR 0.82, 95% CI 0.74 to 0.91, P <.001), overall mortality (HR 0.48, 95% CI 0.41 to 0.57; P <.001), and the composite outcome (HR 0.82, 95% CI 0.74 to 0.91; P <.002) during the consolidated time that patients were exposed to GLP-1RAs compared to corresponding rates during intervals without GLP-1RA exposure. GLP-1RA treatment was associated with a significant decrease in CVA, mortality, and the composite outcome in patients with and without established CVD, not significantly affecting AMI in these subgroups. Conclusions: GLP-1RA exposure was found to be associated with a reduction in the risk of cardiovascular events observed and overall mortality among patients with T2D with and without established CVD, after adjusting for potential confounders.
引用
下载
收藏
页码:1555 / 1561
页数:7
相关论文
共 50 条
  • [41] COPD Exacerbations in Patients With Type 2 Diabetes on Glucagon-like Peptide-1 Receptor Agonists
    Foer, D.
    Strasser, Z. H.
    Cui, J.
    Cahill, K. N.
    Murphy, S. N.
    Karlson, E. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [42] Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes
    De Block, Christophe E. M.
    Dirinck, Eveline
    Verhaegen, Ann
    Van Gaal, Luc F.
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 788 - 805
  • [43] Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes
    Mosenzon, Ofri
    Schechter, Meir
    Leibowitz, Gil
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2021, 28 (04) : 347 - 360
  • [44] Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes
    Tran, Kelvin Lingjet
    Park, Young In
    Pandya, Shalin
    Muliyil, Navin John
    Jensen, Brandon David
    Huynh, Kovin
    Nguyen, Quang T.
    AMERICAN HEALTH AND DRUG BENEFITS, 2017, 10 (04): : 178 - 187
  • [45] Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?
    Wendy H. Updike
    Olivia Pane
    Rachel Franks
    Faizah Saber
    Farah Abdeen
    Derek D. Balazy
    Nicholas W. Carris
    Drugs, 2021, 81 : 881 - 893
  • [46] Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1
    Holst, JJ
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2002, 18 (06) : 430 - 441
  • [47] Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?
    Updike, Wendy H.
    Pane, Olivia
    Franks, Rachel
    Saber, Faizah
    Abdeen, Farah
    Balazy, Derek D.
    Carris, Nicholas W.
    DRUGS, 2021, 81 (08) : 881 - 893
  • [48] The glucagon-like peptide-1 receptor agonist, liraglutide, does not suppress postprandial cholecystokinin in patients with type 1 diabetes
    Johansen, N. J.
    Dejgaard, T. F.
    Frandsen, C. S.
    Lund, A.
    Knop, F. K.
    Rehfeld, J. F.
    Madsbad, S.
    Andersen, H. U.
    DIABETOLOGIA, 2019, 62 : S377 - S378
  • [49] Correlates of Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus (from the Department of Veterans Affairs)
    Al Rifai, Mahmoud
    Vaughan, Elizabeth M.
    Abushamat, Layla A.
    Lee, Michelle
    Ramsey, David J.
    Gupta, Kartik
    Navaneethan, Sankar D.
    Virani, Salim S.
    AMERICAN JOURNAL OF CARDIOLOGY, 2022, 172 : 7 - 10
  • [50] Health Technology Assessment: Evaluation of 7 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
    Xie, Zeyu
    Hu, Jia
    Li, Mengting
    Hu, Xiao
    Chen, Jisheng
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2024, 17 : 1053 - 1067